THU0294 5-year efficacy and safety of apremilast treatment in subjects with psoriatic arthritis: pooled analysis of the palace studies
Arthur Kavanaugh(University of California System), Philip J. Mease(Providence College), Dafna D. Gladman(Toronto Western Hospital), Georg Schett(Karolinska University Hospital), Maria Paris(Amgen (United States)), Lichen Teng(Harbin Medical University), B. Guérette, C J Edwards(University of Southampton), Nikolay Delev(Bristol-Myers Squibb (Sweden))
Cited by 0
Related Papers
The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
|Arthritis Care & Research|2010|3.9k
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
|The Lancet|2000|1.5k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913